The Moderna effect was key in its takeoff on the stock market last year; in fact, this week the López-Belmonte laboratory announced that it had completed the manufacture of the first batches of Moderna’s vaccine for the EU. But Rovi has also relied on other catalysts for this, such as the results of its injectable antipsychotic Doria, Bemiparin, distribution licensing agreements -such as Neparvis® and Volutsa®-, the enoxaparin biosimilar or the new contracts in the manufacturing area. To thirds.
With all this and financial figures that in the first half of 2020 recorded growth of 83% in net profit or 60% in EBITDA, Laboratorios Rovi has become an option for investors.
In fact, if in 2020 the shares added to their titles a revaluation of 55%, the Rovi’s stock future this 2021 it looks flattering. Only in the eight sessions that we have this brand-new year its price already adds 15% more than last year.
In addition, in these days of the new year the laboratory has set new maximum prices at closing practically in all sessions. Yesterday it did it again, closing at 43.30 euros, a price that could exceed today, if its price continues as before.
Learn to invest in the short term
Investment Strategies launches the Practical Trading Program to invest at an Expert level. Learn to invest in the short term with our most complete program!
This morning Rovi it has marked 44.20 euros intraday, overcoming its resistance in the medium and long term, which is 43.8 euros.
If we take into account the opinion of analysts, Rovi is a value to be included in the portfolio. Specifically, the consensus of . advises buying shares of the pharmaceutical laboratory, although it gives you a target price of 40.26 euros, which leaves you without potential.
What will happen in 2021 on the stock market?
The Investment Strategies analysis department analyzes the annual outlook for 2021.
Year II of the Covid, what does the market expect? Don’t miss our special January Magazine on what the market expects for this year on the stock market.
Analytics department outlook for 2021, Stronger and quality stocks to invest,, Premium indicators… all this and much more free for our subscribers.
Subscribe to the Premium service of stock analysis of investment strategies and help us to keep improving. It’s time to support the services you regularly use for your investments.
Discover it here